{"id":"gsk580299-gsk-biological-s-hpv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant HPV virus-like particles (VLPs) that mimic the structure of the virus without containing infectious genetic material. Upon administration, these VLPs trigger both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and eliminate HPV-infected cells before malignant transformation occurs. This preventive approach targets multiple high-risk HPV types to reduce the incidence of HPV-associated cancers.","oneSentence":"GSK580299 is an HPV vaccine that stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types associated with cervical cancer and other HPV-related malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:40.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer and precancerous lesions caused by HPV"},{"name":"Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal)"}]},"trialDetails":[{"nctId":"NCT00799825","phase":"PHASE3","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-01","conditions":"Infections, Papillomavirus","enrollment":346},{"nctId":"NCT00849381","phase":"PHASE3","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Infections, Papillomavirus","enrollment":1239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CervarixTM"],"phase":"phase_3","status":"active","brandName":"GSK580299, GSK Biological's HPV vaccine","genericName":"GSK580299, GSK Biological's HPV vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK580299 is an HPV vaccine that stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types associated with cervical cancer and other HPV-related malignancies. Used for Prevention of cervical cancer and precancerous lesions caused by HPV, Prevention of other HPV-related cancers (anal, oropharyngeal, vulvar, vaginal).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}